Table 11. Correlations between CTC and molecular expression in lung metastatic cancer.
| Molecular expression | Negative, N (%) | Positive, N (%) | Unknown, N (%) | Correlation coefficient | P |
|---|---|---|---|---|---|
| TTF-1 (10%) | 50 (71.43) | 14 (20.00) | 6 (8.57) | −0.447 | 0.37 |
| Calretinin (5%) | 4 (5.71) | 0.000 | 66 (94.29) | 0.049 | 0.62 |
| CD34 (20%) | 23 (32.86) | 19 (27.14) | 28 (40.00) | 0.186 | 0.056 |
| CD56 (5%) | 8 (11.43) | 0.000 | 62 (88.57) | 0.083 | 0.40 |
| CD68 (30%) | 20 (28.57) | 31 (44.29) | 19 (27.14) | 0.010 | 0.92 |
| CDX2 (50%) | 14 (20.00) | 47 (67.14) | 9 (12.86) | 0.137 | 0.16 |
| C-MET (25%) | 16 (22.86) | 6 (8.57) | 48 (68.57) | −0.161 | 0.10 |
| CgA (10%) | 10 (14.29) | 0.000 | 60 (85.71) | −0.060 | 0.54 |
| CK (10%) | 5 (7.14) | 0.000 | 65 (92.86) | 0.127 | 0.19 |
| CK20 (10%) | 11 (15.71) | 1 (1.43) | 58 (82.86) | 0.088 | 0.37 |
| CK7 (10%) | 19 (27.14) | 39 (55.71) | 12 (17.14) | −0.015 | 0.88 |
| CK8/18 (10%) | 8 (11.43) | 5 (7.14) | 57 (81.43) | 0.123 | 0.21 |
| Desmin (1%) | 15 (21.43) | 0.000 | 55 (78.57) | −0.051 | 0.60 |
| E-cadherin (25%) | 35 (50.00) | 18 (25.71) | 17 (24.29) | −0.103 | 0.29 |
| ER (25%) | 2 (2.86) | 5 (7.14) | 63 (90.00) | 0.078 | 0.43 |
| GATA3 (50%) | 21 (30.00) | 12 (17.14) | 37 (52.86) | 0.039 | 0.69 |
| GATA6 (10%) | 36 (51.43) | 7 (10.00) | 27 (38.57) | −0.084 | 0.39 |
| GPA33 (1%) | 3 (4.29) | 0.000 | 67 (95.71) | −0.022 | 0.82 |
| HER2 (50%) | 0.000 | 5 (7.14) | 65 (92.86) | 0.057 | 0.56 |
| HNF4α (1%) | 9 (12.86) | 0.000 | 61 (87.14) | −0.018 | 0.85 |
| Ki-67 (25%) | 20 (28.57) | 42 (60.00) | 8 (11.43) | −0.062 | 0.53 |
| LCA (10%) | 5 (7.14) | 1 (1.43) | 64 (91.43) | 0.017 | 0.86 |
| MTAP (50%) | 7 (10.00) | 0.000 | 63 (90.00) | −0.134 | 0.17 |
| MUC4 (5%) | 20 (28.57) | 13 (18.57) | 37 (52.86) | 0.118 | 0.23 |
| Napsin A (25%) | 32 (45.71) | 6 (8.57) | 32 (45.71) | 0.238 | 0.16 |
| P40 (10%) | 12 (17.14) | 0.000 | 58 (82.86) | −0.001 | 0.99 |
| P53 (50%) | 11 (15.71) | 24 (34.29) | 35 (50.00) | −0.024 | 0.81 |
| Pou2F3 (1%) | 7 (10.00) | 1 (1.43) | 62 (88.57) | −0.118 | 0.23 |
| PD-L1 (1%) | 2 (2.86) | 0.000 | 68 (97.14) | 0.013 | 0.89 |
| PR (5%) | 33 (47.14) | 12 (17.14) | 25 (35.71) | 0.017 | 0.87 |
| SALL4 (25%) | 15 (21.43) | 9 (12.86) | 46 (65.71) | −0.048 | 0.62 |
| SMARCA4 (25%) | 24 (34.29) | 17 (24.29) | 29 (41.43) | −0.017 | 0.86 |
| Villin (10%) | 11 (15.71) | 49 (70.00) | 10 (14.29) | −0.016 | 0.87 |
| WT-1 (1%) | 10 (14.29) | 3 (4.29) | 57 (81.43) | −0.044 | 0.66 |
| ZEB1 (10%) | 12 (17.14) | 0.000 | 58 (82.86) | 0.053 | 0.59 |
| β-catenin (50%) | 20 (28.57) | 15 (21.43) | 35 (50.00) | 0.145 | 0.14 |
For molecular expression, the percentage in parentheses represents the threshold for positive and negative expressions. CTC, circulating tumor cell; TTF-1, thyroid transcription factor-1; CK, cytokeratin; C-MET, cellular-mesenchymal to epithelial transition factor; LCA, leucocyte common antigen; MTAP, methylthioadenosine phosphorylase; ER, estrogen receptor; PD-L1, programmed cell death ligand 1; PR, progesterone receptor; SALL4, spalt-like transcription factor 4; SMARCA4, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin; WT-1, Wilms tumor 1; ZEB1, zinc finger E-box binding homeobox 1.